Macrogenics (MGNX) Cash from Restructuring (2012 - 2018)
Macrogenics (MGNX) reported Cash from Restructuring of -$298000.0 for Q1 2018, up 21.37% year-over-year from -$245526.1 in Q1 2017, and up 28.54% quarter-over-quarter from -$417000.0 in Q4 2017.
Macrogenics (MGNX) Cash from Restructuring (2012 - 2018) Analysis & Trends
Macrogenics (MGNX) has 7 years of Cash from Restructuring data on file, last reported at -$298000.0 in Q1 2018.
- Cash from Restructuring for Q1 2018 came in at -$298000.0, up 21.37% year-over-year; the trailing twelve-month figure through Mar 2019 was -$298000.0 (up 80.29% YoY), and the FY2017 annual result was -$1.6 million, up 43.55% from the prior year.
- Cash from Restructuring improved to -$298000.0 in Q1 2018 per MGNX's latest filing, from -$417000.0 in the prior quarter.
- Over five years, Cash from Restructuring peaked at -$298000.0 in Q1 2018 and troughed at -$2.0 million in Q2 2015.
- A 5-year average of -$555588.2 and a median of -$392000.0 in 2017 frame the typical range for Cash from Restructuring.
- The sharpest annual moves came in 2015 and 2017: Cash from Restructuring plunged 459.72% in 2015, then soared 76.18% in 2017.
- A 5-year view of Cash from Restructuring shows it stood at -$372000.0 in 2014, then fell by 23.66% to -$460000.0 in 2015, then grew by 24.13% to -$349000.0 in 2016, then decreased by 19.48% to -$417000.0 in 2017, then increased by 28.54% to -$298000.0 in 2018.
- Business Quant data shows MGNX's Cash from Restructuring at -$298000.0 in Q1 2018, -$417000.0 in Q4 2017, and -$405000.0 in Q3 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Macrogenics | 260.14 Mn | 193.63 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2018 | -298,000.00 |
| Dec 31, 2017 | -417,000.00 |
| Sep 30, 2017 | -405,000.00 |
| Jun 30, 2017 | -392,000.00 |
| Mar 31, 2017 | -379,000.00 |
| Dec 31, 2016 | -349,000.00 |
| Sep 30, 2016 | -339,000.00 |
| Jun 30, 2016 | -1.65 Mn |
| Mar 31, 2016 | -488,000.00 |
| Dec 31, 2015 | -460,000.00 |
| Sep 30, 2015 | -450,000.00 |
| Jun 30, 2015 | -1.99 Mn |
| Mar 31, 2015 | -396,000.00 |
| Dec 31, 2014 | -372,000.00 |
| Sep 30, 2014 | -364,000.00 |
| Jun 30, 2014 | -355,000.00 |
| Mar 31, 2014 | -348,000.00 |
| Dec 31, 2013 | -163,000.00 |
| Sep 30, 2013 | -159,000.00 |
| Jun 30, 2013 | -155,005.00 |